Moderna (NASDAQ:MRNA - Get Free Report) was downgraded by research analysts at The Goldman Sachs Group from a "buy" rating to a "neutral" rating in a research note issued on Wednesday, MarketBeat Ratings reports. They currently have a $51.00 price objective on the stock, down from their prior price objective of $99.00. The Goldman Sachs Group's price target indicates a potential upside of 13.48% from the stock's current price.
MRNA has been the topic of several other research reports. Sanford C. Bernstein initiated coverage on shares of Moderna in a research note on Thursday, October 17th. They set a "market perform" rating and a $55.00 price objective on the stock. Morgan Stanley dropped their price objective on shares of Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Wednesday, January 15th. Barclays dropped their price objective on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating on the stock in a research note on Friday, November 8th. JPMorgan Chase & Co. dropped their target price on shares of Moderna from $59.00 to $45.00 and set an "underweight" rating on the stock in a research note on Tuesday, November 26th. Finally, Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a "hold" rating in a research note on Thursday, January 16th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $67.26.
Read Our Latest Report on MRNA
MRNA stock opened at $44.94 on Wednesday. Moderna has a 12-month low of $31.94 and a 12-month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm's 50-day moving average price is $40.79 and its two-hundred day moving average price is $62.18. The stock has a market capitalization of $17.29 billion, a price-to-earnings ratio of -7.72 and a beta of 1.60.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion for the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter in the previous year, the company earned ($1.39) earnings per share. Moderna's quarterly revenue was up 3.8% on a year-over-year basis. As a group, equities analysts predict that Moderna will post -9.27 earnings per share for the current year.
In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 2,664 shares of company stock worth $115,210 in the last three months. Company insiders own 15.70% of the company's stock.
A number of large investors have recently made changes to their positions in MRNA. State Street Corp raised its holdings in shares of Moderna by 12.1% in the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock valued at $349,166,000 after purchasing an additional 906,114 shares in the last quarter. Two Sigma Advisers LP bought a new position in shares of Moderna during the 3rd quarter worth approximately $23,825,000. International Assets Investment Management LLC raised its stake in shares of Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company's stock worth $21,353,000 after acquiring an additional 316,552 shares in the last quarter. Finally, Douglas Lane & Associates LLC raised its stake in shares of Moderna by 62.9% during the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company's stock worth $32,175,000 after acquiring an additional 298,715 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.